Moneycontrol PRO
Upcoming Event:Attend Quants League - 5 Days Live Algorithmic Options Trading Virtual Conference @ just Rs. 600/- brought to you by Moneycontrol Pro. Register Now!
you are here: HomeNewsBusiness

Buy Ipca Laboratories; target of Rs 2490: ICICI Direct

ICICI Direct is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 2490 in its research report dated February 05, 2021.

February 10, 2021 / 04:28 PM IST


  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Ipca Laboratories

Q3FY21 revenues grew 16.2% YoY to Rs 1410 crore (I-direct estimate: Rs 1374 crore) mainly due to strong YoY growth of 22.0% in export formulation to Rs 431 crore. API sales also posted robust growth of 23.4% YoY to Rs 352 crore. Domestic formulations grew 7.7% to Rs 523 crore. EBITDA margins improved 346 bps YoY to 26.0% (I-direct estimate of 26.1%) due to lower employee and other expenditure partially offset by lower gross margins. Subsequently, EBITDA grew 34.1% YoY to Rs 367 crore (I-direct estimate: Rs 358 crore). PAT grew 34.3% YoY to Rs 266 crore (I-direct estimate: Rs 262 crore) in line with operational performance.


We maintain BUY and arrive at our target price of Rs 2490 (earlier TP: Rs 2665) based on 25x FY23E EPS of Rs 99.5.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Feb 10, 2021 04:28 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark